What if the biggest risk of chemotherapy isn’t the cancer… but what it does to your immune system?
In this eye-opening episode, Dr. Dino Prato, founder of Envita Medical Centers, explains why conventional chemotherapy — especially when given at maximum tolerated doses — may increase the risk of long-term immune suppression, inflammation, and even resistance.
🧬 Discover how genetically targeted, low-dose chemotherapy (also known as metronomic or fractionated chemotherapy) is designed to support immune function while precisely attacking tumors.
🎯 What You’ll Learn:

• Why standard chemo protocols often don’t match the patient’s unique molecular profile
• The role of DAMPs (Damage-Associated Molecular Patterns) in immune signaling
• How combining genomics, transcriptomics, immune profiling, and targeted delivery methods may reduce toxicity and improve outcomes
• When interventional delivery (chemo directly to the tumor) might offer better precision
• Why timing, dosage, and recovery planning are critical to treatment success
  

At Envita, we believe better data leads to smarter, more immune-friendly cancer care — especially for patients who’ve already failed conventional options.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493